AdventHealth

 

Oncology
17:50

AdventHealth

Clinical Highlights From AACR 2024: Trials Evaluating Selected New Treatments

FEATURING Guru Sonpavde
  • 559 views
  • April 16, 2024
  • 3
13:54

AdventHealth

FDA Approval of Gemcitabine-Cisplatin + Nivo as 1L Therapy for Advanced Urothelial Carcinoma

FEATURING Guru Sonpavde
  • 256 views
  • March 11, 2024
  • 1
14:00

Insights from 2024 ASCO® GU Annual Meeting

ASCO® GU 2024 Summary: "Key Highlights in Bladder/Urothelial Carcinoma"

FEATURING Guru Sonpavde
  • 358 views
  • February 6, 2024
  • 7
31:30

Insights from 2023 ESMO Annual Meeting

ESMO23 Highlights in Urothelial Carcinoma

FEATURING Guru Sonpavde, Bradley McGregor
  • 232 views
  • November 28, 2023
  • 1
22:19

Insights from 2023 ESMO Annual Meeting

Bladder Cancer Highlights From ESMO 2023: Comparing and Contrasting EV302 and CheckMate 901

FEATURING Guru Sonpavde
  • 813 views
  • October 30, 2023
  • 2
13:54

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "Key Bladder Cancer/Urothelial Carcinoma Updates"

FEATURING Guru Sonpavde
  • 368 views
  • June 16, 2023
  • 2
09:12

AdventHealth

Update on the FDA Accelerated Approval of Enfortumab Vedotin + Pembrolizumab for Locally Advanced or Metastatic UC: What This Means in the Clinic

FEATURING Guru Sonpavde
  • 879 views
  • April 11, 2023
  • 4
04:35

ESMO 2022 Conference Coverage

ESMO 2022 on the 4-Factor Model to Predict Response and Survival Benefit With Durvalumab in Previously Treated Metastatic Urinary Tract Carcinoma

FEATURING Guru Sonpavde
  • 127 views
  • September 19, 2022
12:10

ESMO 2022 Conference Coverage

ESMO 2022: Key Bladder Cancer/Urothelial Carcinoma Presentations

FEATURING Guru Sonpavde
  • 802 views
  • September 16, 2022
  • 1
09:01

SABCS 2022 Conference Coverage

Adjuvant Treatment for HR+/HER2-, Node-Positive, High-Risk eBC: 4-Year Results From the monarchE Study

FEATURING Wassim Mchayleh
  • 296 views
  • February 7, 2023
  • 1